PMID- 31365088
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230412
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 104
IP  - 9
DP  - 2019 Sep 1
TI  - Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic 
      Review and Meta-Analysis.
PG  - 3986-3995
LID - 10.1210/jc.2019-01269 [doi]
AB  - CONTEXT: The extent to which some pharmacological interventions reduce or 
      increase the risk of biochemical conversion to type 2 diabetes mellitus (T2DM) in 
      at-risk individuals is unclear. METHODS: We searched MEDLINE, Embase, the 
      Cochrane Central Register of Controlled Trials, the Cochrane Database of 
      Systematic Reviews, and Scopus through 24 August 2017 for randomized controlled 
      trials evaluating the effect of drugs suspected to modify the risk of biochemical 
      conversion to T2DM. RESULTS: We included 43 trials with 192,156 subjects (mean 
      age, 60 years; 56% men; mean body mass index, 30.4 kg/m2). alpha-Glucosidase 
      inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor 
      blockers, metformin, orlistat, phentermine/topiramate, and pioglitazone 
      significantly reduced the risk of biochemical conversion to T2DM, whereas statins 
      and nateglinide increased the risk. There was insufficient direct evidence 
      regarding the effects of sulfonylureas, glucagon-like peptide-1 receptor 
      agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 
      inhibitors. Most trials were brief and evaluated this outcome during treatment 
      without a withdrawal or washout period. CONCLUSIONS: Several drugs modify the 
      risk of biochemical conversation to T2DM, although whether this effect is 
      persistent and clinically relevant is unclear. Future studies need to focus on 
      cardiovascular disease prevention, mortality, and patient-important outcomes 
      instead of biochemical conversion to T2DM.
CI  - Copyright (c) 2019 Endocrine Society.
FAU - Domecq, Juan Pablo
AU  - Domecq JP
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
FAU - Prutsky, Gabriela
AU  - Prutsky G
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
FAU - Elraiyah, Tarig
AU  - Elraiyah T
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
AD  - Division of Nephrology, Department of Medicine, Drexel University College of 
      Medicine, Philadelphia, Pennsylvania.
FAU - Wang, Zhen
AU  - Wang Z
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
FAU - Mauck, Karen F
AU  - Mauck KF
AD  - Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota.
FAU - Brito, Juan Pablo
AU  - Brito JP
AD  - Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.
AD  - Division of Endocrinology, Mayo Clinic, Rochester, Minnesota.
FAU - Undavalli, Chaitanya
AU  - Undavalli C
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
FAU - Sundaresh, Vishnu
AU  - Sundaresh V
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
AD  - Division of Endocrinology, Metabolism, and Diabetes, University of Utah, Salt 
      Lake City, Utah.
FAU - Prokop, Larry J
AU  - Prokop LJ
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
FAU - Montori, Victor M
AU  - Montori VM
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
AD  - Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.
AD  - Division of Endocrinology, Mayo Clinic, Rochester, Minnesota.
FAU - Murad, M Hassan
AU  - Murad MH
AUID- ORCID: 0000-0001-5502-5975
AD  - Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - IM
EDAT- 2019/08/01 06:00
MHDA- 2019/08/01 06:01
CRDT- 2019/08/01 06:00
PHST- 2019/06/05 00:00 [accepted]
PHST- 2019/06/04 00:00 [received]
PHST- 2019/08/01 06:01 [medline]
PHST- 2019/08/01 06:00 [pubmed]
PHST- 2019/08/01 06:00 [entrez]
AID - 5540923 [pii]
AID - 10.1210/jc.2019-01269 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2019 Sep 1;104(9):3986-3995. doi: 10.1210/jc.2019-01269.